Multi-center study on Alzheimer's disease using FDG PET: Group and individual analyses

Journal of Alzheimer's Disease

Volumn 19, Issue 3, 2010, Pages 927-935

  Yuan, Xiuli ^a   Shan, Baoci ^a   Ma, Yunchuan ^b   Tian, Jiahe ^c   Jiang, Kaida ^d   Cao, Qiuyun ^d   Wang, Ruimin ^c  

^a INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

Alzheimer's disease; Hypo metabolism; Individual analysis; Multicenter study; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; MULTICENTER STUDY; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; TEMPORAL LOBE; THREE DIMENSIONAL IMAGING;

EID: 77149159456     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1287     Document Type: Article

References (29)

1. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, Heiss WD (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17, 302-316.
2. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159, 738-745.
3. Silverman DH, Small GW, Phelps ME (1999) Clinical value of neuroimaging in the diagnosis of dementia. Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging 2, 119-130.
4. Silverman DH, SmallGW, Chang CY, Lu CS,Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286, 2120-2127.
5. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334, 752-758.
6. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32, 486-510.
7. Rimajova M, Lenzo NP,Wu JS, Bates KA, Campbell A, Dhaliwal SS, McCarthy M, Rodrigues M, Paton A, Rowe C, Foster JK, Martins RN (2008) Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population. J Alzheimers Dis 13, 137-146.
8. Duara R, Grady C, Haxby J, Sundaram M, Cutler NR, Heston L, Moore A, Schlageter N, Larson S, Rapoport SI (1986) Positron emission tomography in Alzheimer's disease. Neurology 36, 879-887.
9. Herholz K (1995) FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 9, 6-16.
10. Ishii K (2002) Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 16, 515-525. (Pubitemid 36205668)
11. Herholz K (2003) PET studies in dementia. Ann Nucl Med 17, 79-89.
12. Jagust W(2004) Molecular neuroimaging in Alzheimer's disease. NeuroRx 1, 206-212.
13. Herholz K, Perani D, Salmon E, Franck G, Fazio F, Heiss WD, Comar D (1993) Comparability of FDG PET studies in probable Alzheimer's disease. J Nucl Med 34, 1460-1466.
14. Del Sole A, Clerici F, Chiti A, Lecchi M, Mariani C, Maggiore L, Mosconi L, Lucignani G (2008) Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study. Eur J Nucl Med Mol Imaging 35, 1357-1366.
15. Talairach J, Tournoux P (1988) Co-planar stereotactic atlas of human brain. Thieme Medical Publishers, Inc. New York.
16. Friston K, AP H, KJ W (1995) Statistical parametric maps in functional imaging: A general linear approach. Human Brain Mapping 2, 189-210.
17. Signorini M, Paulesu E, Friston K, Perani D, Colleluori A, Lucignani G, Grassi F, Bettinardi V, Frackowiak RS, Fazio F (1999) Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping. Neuroimage 9, 63-80.
18. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G (1983) Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 33, 961-965.
19. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE (1983) Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [F]fluorodeoxyglucose. J Comput Assist Tomogr 7, 590-598.
20. Ishii K, Sasaki M, Kitagaki H,Yamaji S, Sakamoto S, Matsuda K, Mori E (1997) Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 38, 925-928.
21. Ibanez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, Rapoport SI, Schapiro MB, Horwitz B (1998) Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 50, 1585-1593.
22. Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, Hirono N, Mori E (2002) Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci 200, 27-32.
23. Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, Matsuda H, Mori E (2006) Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 33, 801-809.
24. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42, 85-94.
25. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE (1995) A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36, 1238-1248.
26. Desgranges B, Baron JC, de la Sayette V, Petit-Taboue MC, Benali K, Landeau B, Lechevalier B, Eustache F (1998) The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain 121(Pt 4), 611-631.
27. Ashford JW, Shih WJ, Coupal J, Shetty R, Schneider A, Cool C, Aleem A, Kiefer VH, Mendiondo MS, Schmitt FA (2000) Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity in Alzheimer's disease. J Nucl Med 41, 57-64.
28. Yakushev I, Hammers A, Fellgiebel A, Schmidtmann I, Scheurich A, Buchholz HG, Peters J, Bartenstein P, Lieb K, Schreckenberger M (2009) SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. NeuroImage 44, 43-50.
29. AshfordJW(2008) Screening for memory disorders, dementia and Alzheimer's disease. Aging Health 4, 399-432.